Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials.

This article focuses on the analysis of clinical trial data evaluating lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor, as a potential disease-modifying treatment for knee osteoarthritis (OA). Data from two Phase 2 and two Phase 3 trials involving patients with Kellgren-Lawrence (KL) Grades 2–3 knee OA revealed substantial heterogeneity in baseline joint structural damage, particularly medial joint space width (JSW). The findings indicate that LOR demonstrated greater symptomatic improvements in patients with less advanced structural damage (higher medial JSW and KL grade 2), suggesting an association between OA structural severity and pain response. These results support the hypothesis that early intervention in knee OA may yield better clinical outcomes and highlight the need for refined structural inclusion criteria in future OA trials.